{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:21:52Z","timestamp":1790270512133,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Grant from Gangnam Severance Hospital","award":["D-2023-0012"],"award-info":[{"award-number":["D-2023-0012"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00405287"],"award-info":[{"award-number":["RS-2024-00405287"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2025-00562090"],"award-info":[{"award-number":["2025-00562090"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12199-w","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:26:47Z","timestamp":1754404007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases"],"prefix":"10.1038","volume":"15","author":[{"given":"Wungrak","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"12199_CR1","first-page":"1017","volume":"78","author":"RE Gilbert","year":"1998","unstructured":"Gilbert, R. E. et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab. Investig. 78, 1017\u20131027 (1998).","journal-title":"Lab. Investig."},{"key":"12199_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2337\/diabetes.47.3.401","volume":"47","author":"HP Hammes","year":"1998","unstructured":"Hammes, H. P., Lin, J., Bretzel, R. G., Brownlee, M. & Breier, G. Upregulation of the vascular endothelial growth factor\/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 47, 401\u2013406 (1998).","journal-title":"Diabetes"},{"key":"12199_CR3","first-page":"844","volume":"82","author":"S Resnikoff","year":"2004","unstructured":"Resnikoff, S. et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844\u2013851 (2004).","journal-title":"Bull. World Health Organ."},{"key":"12199_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn, J. S. et al. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 27, 331\u2013371 (2008).","journal-title":"Prog. Retin. Eye Res."},{"key":"12199_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung, N., Mitchell, P. & Wong, T. Y. Diabetic retinopathy. Lancet (London England). 376, 124\u2013136 (2010).","journal-title":"Lancet (London England)"},{"key":"12199_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jdi.13480","volume":"12","author":"KY Lin","year":"2021","unstructured":"Lin, K. Y., Hsih, W. H., Lin, Y. B., Wen, C. Y. & Chang, T. J. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J. Diabetes Investig. 12, 1322\u20131325 (2021).","journal-title":"J. Diabetes Investig."},{"key":"12199_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/01.iio.0000212142.15794.30","volume":"46","author":"PU Dugel","year":"2006","unstructured":"Dugel, P. U. Ranibizumab treatment of patients with ocular diseases. Int. Ophthalmol. Clin. 46, 131\u2013140 (2006).","journal-title":"Int. Ophthalmol. Clin."},{"key":"12199_CR8","doi-asserted-by":"publisher","first-page":"623e621","DOI":"10.1016\/j.ophtha.2006.01.027","volume":"113","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J., Heier, J. S., Hantsbarger, G. & Shams, N. Tolerability and efficacy of multiple escalating doses of Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 113, 623e621 (2006).","journal-title":"Ophthalmology"},{"key":"12199_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4103\/0301-4738.36474","volume":"55","author":"S Grisanti","year":"2007","unstructured":"Grisanti, S. & Ziemssen, F. Bevacizumab: off-label use in ophthalmology. Indian J. Ophthalmol. 55, 417\u2013420 (2007).","journal-title":"Indian J. Ophthalmol."},{"key":"12199_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3341\/kjo.2016.30.4.265","volume":"30","author":"DK Lee","year":"2016","unstructured":"Lee, D. K., Kim, S. H., You, Y. S. & Kwon, O. W. High dose intravitreal bevacizumab for refractory pigment epithelial detachment in age-related macular degeneration. Korean J. Ophthalmol. KJO. 30, 265\u2013271 (2016).","journal-title":"Korean J. Ophthalmol. KJO"},{"key":"12199_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.eye.6702980","volume":"23","author":"JF Arevalo","year":"2009","unstructured":"Arevalo, J. F. et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (London England). 23, 117\u2013123 (2009).","journal-title":"Eye (London England)"},{"key":"12199_CR12","doi-asserted-by":"crossref","unstructured":"Stewart, M. W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 87, 77\u201388 (2012).","DOI":"10.1016\/j.mayocp.2011.10.001"},{"key":"12199_CR13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/bjo.2006.095190","volume":"90","author":"MS Spitzer","year":"2006","unstructured":"Spitzer, M. S. et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br. J. Ophthalmol. 90, 1316\u20131321 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"12199_CR14","doi-asserted-by":"publisher","first-page":"12409","DOI":"10.1038\/s41598-020-68488-z","volume":"10","author":"N Froger","year":"2020","unstructured":"Froger, N. et al. VEGF is an autocrine\/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci. Rep. 10, 12409 (2020).","journal-title":"Sci. Rep."},{"key":"12199_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.npep.2010.04.002","volume":"44","author":"A Sanchez","year":"2010","unstructured":"Sanchez, A., Wadhwani, S. & Grammas, P. Multiple neurotrophic effects of VEGF on cultured neurons. Neuropeptides. 44, 323\u2013331 (2010).","journal-title":"Neuropeptides"},{"key":"12199_CR16","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3390\/ijms11082875","volume":"11","author":"T Falk","year":"2010","unstructured":"Falk, T., Gonzalez, R. T. & Sherman, S. J. The Yin and Yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of parkinson\u2019s disease. Int. J. Mol. Sci. 11, 2875\u20132900 (2010).","journal-title":"Int. J. Mol. Sci."},{"key":"12199_CR17","first-page":"5717","volume":"7","author":"B Lv","year":"2014","unstructured":"Lv, B., Wang, R., Gao, X., Dong, X. & Ji, X. Effect of vascular endothelial growth factor on retinal ganglion cells of rats with chronic intraocular hypertension. Int. J. Clin. Exp. Pathol. 7, 5717\u20135724 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"12199_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/bjo.80.5.389","volume":"80","author":"HA Quigley","year":"1996","unstructured":"Quigley, H. A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80, 389\u2013393 (1996).","journal-title":"Br. J. Ophthalmol."},{"key":"12199_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262\u2013267 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"12199_CR20","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 121, 2081\u20132090 (2014).","journal-title":"Ophthalmology"},{"key":"12199_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00055735-200304000-00006","volume":"14","author":"DR Anderson","year":"2003","unstructured":"Anderson, D. R. Collaborative normal tension glaucoma study. Curr. Opin. Ophthalmol. 14, 86\u201390 (2003).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"12199_CR22","doi-asserted-by":"crossref","unstructured":"Kass, M. A. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of ophthalmology (Chicago, Ill. : 1960). 120, 701\u2013713  (2002) (discussion 829\u2013730).","DOI":"10.1001\/archopht.120.6.701"},{"key":"12199_CR23","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.visres.2007.07.011","volume":"47","author":"SH Park","year":"2007","unstructured":"Park, S. H., Kim, J. H., Kim, Y. H. & Park, C. K. Expression of neuronal nitric oxide synthase in the retina of a rat model of chronic glaucoma. Vision. Res. 47, 2732\u20132740 (2007).","journal-title":"Vision. Res."},{"key":"12199_CR24","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/01.STR.0000080381.76409.B2","volume":"34","author":"K Prass","year":"2003","unstructured":"Prass, K. et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke. 34, 1981\u20131986 (2003).","journal-title":"Stroke"},{"key":"12199_CR25","doi-asserted-by":"crossref","unstructured":"Bae, H. W. et al. Effects of hypoxic preconditioning and vascular endothelial growth factor on the survival of isolated primary retinal ganglion cells. Biomolecules. 11 (2021).","DOI":"10.3390\/biom11030391"},{"key":"12199_CR26","first-page":"2922","volume":"18","author":"S Hong","year":"2012","unstructured":"Hong, S., Iizuka, Y., Kim, C. Y. & Seong, G. J. Isolation of primary mouse retinal ganglion cells using immunopanning-magnetic separation. Mol. Vis. 18, 2922\u20132930 (2012).","journal-title":"Mol. Vis."},{"key":"12199_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/iovs.63.9.4","volume":"63","author":"K Lee","year":"2022","unstructured":"Lee, K., Choi, J. O., Hwang, A., Bae, H. W. & Kim, C. Y. Ciliary neurotrophic factor derived from astrocytes protects retinal ganglion cells through PI3K\/AKT, JAK\/STAT, and MAPK\/ERK pathways. Investig. Ophthalmol. Vis. Sci. 63, 4 (2022).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"12199_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/978-1-0716-0783-1_30","volume":"2180","author":"LA Marquez-Curtis","year":"2021","unstructured":"Marquez-Curtis, L. A., Eskandari, N., McGann, L. E. & Elliott, J. A. W. Protocol for cryopreservation of endothelial monolayers. Methods Mol. Biol. (Clifton N J). 2180, 581\u2013591 (2021).","journal-title":"Methods Mol. Biology (Clifton N J)"},{"key":"12199_CR29","doi-asserted-by":"publisher","first-page":"e0159182","DOI":"10.1371\/journal.pone.0159182","volume":"11","author":"J Gim","year":"2016","unstructured":"Gim, J., Won, S., Park, T. & LPEseq: Local-pooled-error test for RNA sequencing experiments with a small number of replicates. PLoS One. 11, e0159182 (2016).","journal-title":"PloS One"},{"key":"12199_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.stemcr.2018.02.010","volume":"10","author":"KB Langer","year":"2018","unstructured":"Langer, K. B. et al. Retinal ganglion cell diversity and subtype specification from human pluripotent stem cells. Stem Cell. Rep. 10, 1282\u20131293 (2018).","journal-title":"Stem Cell. Rep."},{"key":"12199_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-023-00655-y","volume":"18","author":"JR Soucy","year":"2023","unstructured":"Soucy, J. R. et al. Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe consortium. Mol. Neurodegener. 18, 64 (2023).","journal-title":"Mol. Neurodegener."},{"key":"12199_CR32","first-page":"1848","volume":"16","author":"VS Brar","year":"2010","unstructured":"Brar, V. S., Sharma, R. K., Murthy, R. K. & Chalam, K. V. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol. Vis. 16, 1848\u20131853 (2010).","journal-title":"Mol. Vis."},{"key":"12199_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.brainres.2012.08.014","volume":"1478","author":"MR Romano","year":"2012","unstructured":"Romano, M. R. et al. Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res. 1478, 55\u201363 (2012).","journal-title":"Brain Res."},{"key":"12199_CR34","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/IJG.0000000000000776","volume":"26","author":"WJ Lee","year":"2017","unstructured":"Lee, W. J. et al. Rate of macular ganglion Cell-inner plexiform layer thinning in glaucomatous eyes with vascular endothelial growth factor Inhibition. J. Glaucoma. 26, 980\u2013986 (2017).","journal-title":"J. Glaucoma"},{"key":"12199_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2016.04.003","volume":"167","author":"M Beck","year":"2016","unstructured":"Beck, M., Munk, M. R., Ebneter, A., Wolf, S. & Zinkernagel, M. S. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am. J. Ophthalmol. 167, 10\u201317 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"12199_CR36","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries, V. A., Bassil, F. L. & Ramdas, W. D. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci. Rep. 10, 13248 (2020).","journal-title":"Sci. Rep."},{"key":"12199_CR37","first-page":"406","volume":"56","author":"A Kopi\u0107","year":"2017","unstructured":"Kopi\u0107, A. et al. Retinal nerve fiber layer thickness in glaucoma patients treated with multiple intravitreal anti-Vegf (Bevacizumab) injections. Acta Clin. Croatica. 56, 406\u2013414 (2017).","journal-title":"Acta Clin. Croatica"},{"key":"12199_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.exer.2016.08.006","volume":"151","author":"B Mead","year":"2016","unstructured":"Mead, B. & Tomarev, S. Evaluating retinal ganglion cell loss and dysfunction. Exp. Eye Res. 151, 96\u2013106 (2016).","journal-title":"Exp. Eye Res."},{"key":"12199_CR39","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb, R. N., Aung, T. & Medeiros, F. A. The pathophysiology and treatment of glaucoma: a review. JAMA 311, 1901\u20131911 (2014).","journal-title":"JAMA"},{"key":"12199_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin, A. M., Chaya, C. J., Kahook, M. Y. & Wirostko, B. M. Intraocular pressure elevation following intravitreal Anti-VEGF injections: Short- and Long-term considerations. J. Glaucoma. 30, 1019\u20131026 (2021).","journal-title":"J. Glaucoma"},{"key":"12199_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3928\/15428877-20090430-12","volume":"40","author":"MY Kahook","year":"2009","unstructured":"Kahook, M. Y. et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg. Lasers Imaging. 40, 293\u2013295 (2009).","journal-title":"Ophthalmic Surg. Lasers Imaging."},{"key":"12199_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0304-3940(01)01830-4","volume":"305","author":"ML Ko","year":"2001","unstructured":"Ko, M. L., Hu, D. N., Ritch, R., Sharma, S. C. & Chen, C. F. Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats. Neurosci. Lett. 305, 139\u2013142 (2001).","journal-title":"Neurosci. Lett."},{"key":"12199_CR43","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1167\/iovs.08-3013","volume":"50","author":"ME Pease","year":"2009","unstructured":"Pease, M. E. et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Investig. Ophthalmol. Vis. Sci. 50, 2194\u20132200 (2009).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"2","key":"12199_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1523\/JNEUROSCI.20-02-00722.2000","volume":"20","author":"P Kermer","year":"2000","unstructured":"Kermer, P., Kl\u00f6cker, N., Labes, M. & B\u00e4hr, M. Insulin-Like growth Factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-Dependent Akt phosphorylation and inhibition of Caspase-3 in vivo. J. Neurosci. 20 (2), 722\u2013728. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-02-00722.2000 (2000).","journal-title":"J. Neurosci."},{"key":"12199_CR45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","volume":"6","author":"DI Holmes","year":"2005","unstructured":"Holmes, D. I. & Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 6, 209 (2005).","journal-title":"Genome Biol."},{"key":"12199_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5483\/BMBRep.2018.51.2.233","volume":"51","author":"SA Park","year":"2018","unstructured":"Park, S. A., Jeong, M. S., Ha, K. T. & Jang, S. B. Structure and function of vascular endothelial growth factor and its receptor system. BMB Rep. 51, 73\u201378 (2018).","journal-title":"BMB Rep."},{"key":"12199_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4161\/org.6.2.11687","volume":"6","author":"JM Rosenstein","year":"2010","unstructured":"Rosenstein, J. M., Krum, J. M. & Ruhrberg, C. VEGF in the nervous system. Organogenesis. 6, 107\u2013114 (2010).","journal-title":"Organogenesis"},{"key":"12199_CR48","doi-asserted-by":"publisher","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on M\u00fcller cells and photoreceptors. PLoS One. 3, e3554 (2008).","journal-title":"PLoS One"},{"key":"12199_CR49","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1167\/iovs.05-1229","volume":"47","author":"M Saint-Geniez","year":"2006","unstructured":"Saint-Geniez, M., Maldonado, A. E. & D\u2019Amore, P. A. VEGF expression and receptor activation in the choroid during development and in the adult. Investig. Ophthalmol. Vis. Sci. 47, 3135\u20133142 (2006).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"12199_CR50","doi-asserted-by":"publisher","first-page":"12439","DOI":"10.1523\/JNEUROSCI.0434-06.2006","volume":"26","author":"U Kilic","year":"2006","unstructured":"Kilic, U. et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1\/2 and Akt pathways. J. Neurosci. 26, 12439\u201312446 (2006).","journal-title":"J. Neurosci."},{"key":"12199_CR51","first-page":"145","volume":"201","author":"J Hasskarl","year":"2014","unstructured":"Hasskarl, J. Sorafenib: targeting multiple tyrosine kinases in cancer. Recent. Results cancer Res. Fortschr. Der Krebsforschung Progres Dans Les Recherches Sur Le cancer. 201, 145\u2013164 (2014).","journal-title":"Recent. Results cancer Res. Fortschr. Der Krebsforschung Progres Dans Les Recherches Sur Le cancer"},{"key":"12199_CR52","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"12199_CR53","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/bjo.2010.182162","volume":"94","author":"M Kernt","year":"2010","unstructured":"Kernt, M. et al. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. Br. J. Ophthalmol. 94, 1533\u20131539 (2010).","journal-title":"Br. J. Ophthalmol."},{"key":"12199_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/08977191003604505","volume":"28","author":"M Kernt","year":"2010","unstructured":"Kernt, M. et al. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors (Chur Switzerland). 28, 211\u2013220 (2010).","journal-title":"Growth Factors (Chur Switzerland)"},{"key":"12199_CR55","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1097\/IAE.0b013e318240a558","volume":"32","author":"M Kernt","year":"2012","unstructured":"Kernt, M. et al. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Retina (Philadelphia Pa). 32, 1652\u20131663 (2012).","journal-title":"Retina (Philadelphia Pa)"},{"key":"12199_CR56","first-page":"198","volume":"7","author":"LL Tian","year":"2014","unstructured":"Tian, L. L. et al. Inhibition of retinopathy of prematurity in rat by intravitreal injection of Sorafenib. Int. J. Ophthalmol. 7, 198\u2013204 (2014).","journal-title":"Int. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12199-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:54:23Z","timestamp":1757357663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12199-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12199-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4925128\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28587"}}